Vaccines stimulate the immune system to produce immune responses that protect against infection. Vaccines provide a safe, cost-effective and efficient means of preventing illness, disability and death from infectious diseases.
Why Is Vaccine Research a Priority for NIAID?
Vaccines have saved millions of lives worldwide and dramatically reduced the prevalence of many life-threatening infectious diseases. Yet there remains a need for new and improved vaccines against existing infectious diseases, as well as a need for rapid development of experimental vaccines to address emerging infectious diseases. NIAID supports and conducts research to identify new vaccine candidates to prevent a variety of infectious diseases, including those for which no vaccines currently exist. NIAID-supported research also aims to improve the safety and efficacy of existing vaccines.
How Is NIAID Addressing This Important Area of Study?
NIAID conducts and supports numerous stages of the vaccine development process, ranging from basic immunology research to clinical testing of candidate vaccines. Basic research aims to understand the complex interactions between pathogens and their human hosts and generate the knowledge essential for developing safe and effective vaccines. Preclinical research helps advance promising vaccine candidates into human testing. Clinical trials evaluate the safety, tolerability and efficacy of investigational vaccines in people.
- Clinical Trial of HIV Vaccine Begins in United States and South Africa
September 20, 2023
- NIH Clinical Trial of Universal Flu Vaccine Candidate Begins
September 15, 2023
NIAID Now Blog
Related Public Health and Government Information
For general health information about vaccines, visit Vaccines.gov and the Centers for Disease Control and Prevention’s Vaccines & Immunizations site. Vaccines are held to very high safety standards; for more information, see the Vaccine Safety page on Vaccines.gov.